Provenienza dei contatti di primo grado di Martin Zillmann
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Pillar Biosciences, Inc.
Pillar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Martin Zillmann tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Affyimmune Therapeutics, Inc.
Affyimmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Affyimmune Therapeutics, Inc. engages in the development of engineered immune cells to fight cancer disease. The company was founded by Gang Song on August 16, 2016 and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member Founder | |
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Pharmaceuticals: Major | Director of Finance/CFO | |
Deciduous Therapeutics, Inc.
Deciduous Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong. | Investment Managers | Private Equity Investor | |
The University of Waterloo | College/University | Undergraduate Degree | |
The Trustees of Columbia University in The City of New York | College/University | Doctorate Degree | |
Gen-Probe, Inc.
Gen-Probe, Inc. Medical SpecialtiesHealth Technology Gen-Probe, Inc. develops, manufactures and markets rapid, accurate and molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. It also develops and manufactures the PROCLEIX assays, which are used to detect human immunodeficiency virus, the hepatitis C virus, the hepatitis B virus, and the West Nile virus in donated human blood. The firm's clinical diagnostics products include APTIMA family of assays, which are used to detect the common STDs chlamydia and gonorrhea. Gen-Probe was founded by Thomas H. Adams and David E. Kohne in 1983 and is headquartered in San Diego, CA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
OnCusp Therapeutics6
OnCusp Therapeutics6 Miscellaneous Commercial ServicesCommercial Services OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then. | Miscellaneous Commercial Services | Director/Board Member | |
Eyecool Therapeutics, Inc.
Eyecool Therapeutics, Inc. Medical SpecialtiesHealth Technology Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA. | Medical Specialties | Director/Board Member | |
The University of Law Ltd. | College/University | Graduate Degree | |
Brixton Biosciences, Inc.
Brixton Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain. | Miscellaneous Commercial Services | Founder | |
IDRx, Inc.
IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Miscellaneous Commercial Services | Founder | |
EQRX, INC. | Pharmaceuticals: Major | Founder | |
EQRx International, Inc.
EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
IMMUNOMEDICS, INC. | Biotechnology | Director/Board Member | |
SevenOaks Biosystems LLC
SevenOaks Biosystems LLC Medical SpecialtiesHealth Technology Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016. | Medical Specialties | Director/Board Member | |
GELESIS INC | Biotechnology | Director/Board Member | |
VERASTEM, INC. | Biotechnology | Chief Executive Officer | |
Rhapsody Biologics, Inc.
Rhapsody Biologics, Inc. BiotechnologyHealth Technology Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA. | Biotechnology | Director/Board Member | |
Atlantic Healthcare Plc
Atlantic Healthcare Plc Pharmaceuticals: MajorHealth Technology Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Bristol | College/University | Graduate Degree | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Chief Operating Officer | |
MYREXIS, INC. | Financial Conglomerates | Director/Board Member | |
Shanghai Medical College of Fudan University | College/University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 23 |
Regno Unito | 4 |
Canada | 3 |
Hong Kong | 2 |
Cina | 2 |
Settori
Health Technology | 18 |
Consumer Services | 6 |
Commercial Services | 5 |
Finance | 4 |
Posizioni
Director/Board Member | 23 |
Founder | 7 |
Independent Dir/Board Member | 5 |
Director of Finance/CFO | 3 |
Graduate Degree | 3 |
Contatti più connessi
Insiders | |
---|---|
Robert M. Forrester | 25 |
Eric Lai | 4 |
Gang Song | 4 |
Zhaohui Wang | 1 |
Hong Fang Sang | 1 |
Hui Yang | 1 |
Shawn Liu | 1 |
Randy Pritchard | 1 |
- Borsa valori
- Insiders
- Martin Zillmann
- Connessioni Società